Earlier this week, AVEO Oncology (AVEO) and Astellas Pharma Inc.(TSE: 4503) announced new data from the Phase III TIVO-1 trial, and we asked the company to provide more insight into its presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback